- Based on the data from the first 4 cohorts and recommendation from the DSMB, a fifth cohort may be necessary to enroll. Another 20 subjects may be administered SB 9200 or matching placebo administered QD for 12 weeks. All subjects will then receive tenofovir 300 mg QD for an additional 12 weeks of treatment.